Mon 6 Jul 2009 | 4:44 IST
You are here: Home > Money > Article
Home
Money
Business News
Markets
Deals
Industries
Quotes
Funds
Currencies
Personal Finance
Portfolio
News
Do More With Reuters
RSSRSS Feed
Widgets
Mobile
Newsletters
Partner Services
City SearchNew
About Thomson Reuters

Cadila Health gets US nod for bromocriptine mesylate

Fri Aug 1, 2008 3:14pm IST
 
Email | Print | | Single Page
[-] Text [+]

MUMBAI, Aug 1 (Reuters) - Drug maker Cadila Healthcare Ltd (CADI.BO: Quote, Profile, Research) said on Friday it received the U.S. Food and Drug Administration approval for its generic bromocriptine mesylate capsules.

The drug, used to treat problems with menstrual period and infertility in women, had sales of $11.4 million in 2007, the company said in a statement. (Reporting by Bharghavi Nagaraju; Editing by Ramya Venugopal)

special coverage

Budget 2009
Budget 2009

The government presents the budget for the full fiscal year 2009/10 on July 6.  Full Coverage 

Market Update

  • IndiaIndia
  • USUS
  • UKUK
  • Asia
  • Most Actives

SHOWCASE

Photo
Is the budget over-rated for personal finance?

Expectations are high given the outcome in the general elections.  Commentary 

 
Nilekani: Infosys' loss or govt’s gain?
Nilekani: Infosys' loss or govt’s gain?

Nandan Nilekani has resigned from the Infosys board to join the government.  Commentary | Slideshow 

 
JLR in IndiaSlideshowSlideshow 
Launched

Tata Motors announced the launch of Jaguar and Land Rover vehicles in India.  Slideshow | Video 

JLR launched
 
Satyam
The new Satyam

Stay updated with the developments at Satyam.  Full Coverage 

 
M&A Review
M&A Review

A review of mergers and acquisitions.  Full Coverage 

 
Financial Turmoil Timeline
Financial Turmoil Timeline

A round-up of measures taken by the U.S Federal Reserve since June 2007 to tackle the financial crisis.  Full Coverage